Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

4Total
P 1 (2)
P 2 (2)

Trial Status

Active Not Recruiting3
Completed1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT02867592Phase 2Active Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT04514484Phase 1Active Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04877613Phase 1Active Not Recruiting

GFRα4 CAR T Cells in MTC Patients

NCT00390325Phase 2Completed

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Showing all 4 trials

Research Network

Activity Timeline